Dr. Birgit GEOERGER (MD,PhD) –  Pediatric Oncologist, Ewing’s Sarcoma Coordinator

Dr. Birgit Geoerger is pediatric oncologist heading the Pediatric Early Drug Development Program in the Department of Pediatric and Adolescent Oncology at Gustave Roussy Cancer Center in Villejuif, France. Dr. Geoerger has an international career and is a key opinion leader in childhood cancer drug development and chaired the Clinical Trial Committee of the Innovation Therapies for Children with Cancer (ITCC) Consortium during 11 years.

She has initiated the MAPPYACTS profiling program and the AcSé-ESMART molecularly guided precision medicine therapeutic platform trial, both sponsored by Gustave Roussy, and is coordinating the pediatric relapse indication of the France Medécine Génomique 2025 program and the ambitious MAPPYACTS 2 study. She had developed and contributed to multiple early clinical, first-in-child and first-in-class trials. Her laboratory group in the INSERM U1015 research laboratory of Prof Laurence Zitvogel aims at developing new therapies for pediatric cancers. She authored more than 130 peer-reviewed publications.

Pierre Busson: is a Senior Research Scientist at the CNRS and Gustave Roussy (DR1 CNRS, UMR 9018, Villejuif, France). He obtained his M.D. in 1983 and his Ph.D. in Virology in 1990 from Paris University. Following a post-doctoral research fellowship at the Lineberger Cancer Research Center (Chapel Hill, North Carolina, USA), he was recruited by the CNRS (National Center for Scientific Research). Most contributions of his group were on virus-cell and host-tumor interactions in Epstein-Barr virus-associated nasopharyngeal carcinomas (NPC). He was invited speaker at the Gordon Research Conferences on Nasopharyngeal Carcinomas organized in Hong-Kong (2018) and Castelldefels (2022). He is author in more than 110 articles in peer-reviewed scientific journals and seven book chapters (H-index 49). He has supervised 14 PhD theses. He teaches undergraduate and graduate students at Gustave Roussy and Paris-Saclay University. He is a grant reviewer for several institutions in France, Europe and Hong-Kong. He is academic editor for PLoS One and ad hoc reviewer for about 20 journals.

Dr. Alexandra LEARY (MD, PhD) – Medical Oncologist, Endometrial Cancer Coordinator

Alexandra Leary is a Medical Oncologist and Translational Researcher specializing in gynaecological tumors at Gustave Roussy, with a special focus on early phase drug development. Dr Leary is also team leader for gynaecological oncology translational research within the laboratory of Predictive Biomarkers and Novel Targeted Therapeutics (INSERM U981) at Gustave Roussy. 

She sits on the board of the French clinical trial intergroup, GINECO, and is President of the GINECO Group on Early Phase Studies (GINEGEPS). Internationally, she is a member of the ENGOT (European Network of Gynaecological Oncological Trial groups) translational research group, French representative at the Gynecologic Cancer InterGroup (GCIG), co-Chair of the GCIG phase II trial group, European Society for Medical Oncology (ESMO) faculty and gynaecology track Chair.

Hollebecque Biography

Antoine Hollebecque (M.D.) is a senior medical oncologist at Gustave Roussy Cancer Center in Paris. He completed his residency training in 2008. He spent 2 years as an Assistant Professor in the Drug Development Department at Gustave Roussy Cancer Center in 2012-2013. He completed his training with a one-year post-doctoral fellowship in the Clinical and Experimental Pharmacology (CEP) (Pr C. Dive), Manchester Institute, Cancer Research UK where he worked on cell-free DNA. His research axis are precision medicine, biliary and pancreatic carcinoma, FGFR inhibitors and drug development. Dr Hollebecque is or has been the principal investigator of more than 50 Phase I/II/III trials and investigator of more than 400 clinical trials over the past ten years. He has contributed to more than 230 peer-reviewed publications, including publications in the New England Journal of Medicine, Nature Medicine, Cancer Discovery, Journal of Clinical Oncology, Annals of oncology, JAMA Oncology, Gastroenterology. Dr Hollebecque is a member of the European Society of Medical Oncology (ESMO), American Association of Clinical Oncology (ASCO) and the French Federation of Gastrointestinal oncology (FFCD).

Yohann Loriot, MD, PhD received his MD in Paris in 2009 and a PhD in Cancer biology from Paris University in 2014. He is a medical oncologist working at Gustave Roussy and taking care of patients presenting GU cancer (urothelial, prostate and testis cancer).  He is a past recipent of Young oncologist Award from American Society of Clinical oncology. He is currently Head of GU oncology group  at Gustave Roussy and Deputy chair of the departement of early drug development.

His major research work focuses on drug development with connection with the field of biomarker discovery, development of targeted therapies and immunotherapies. His team of 20 people aims to identify mechanisms of action  and resistance to innovative therapies working on basic sciences, bioinformatics and clinical research. He’s also leading  phase I-III trials testing new drugs in urothelial and prostate cancers. Dr Loriot is currently member of steering committee of multiple international clinical trials from phase I to phase III which led to several drug approvals (erdafitinib, enzalutamide, abiraterone, atezolizumab, sacituzumab, enfortumab). Dr Loriot has published more than 200 peer reviewed papers including papers in New england journal of medicine, Lancet Oncology, Cancer Discovery as main or senior author. Dr Loriot  is member of several scientific committees for international academic groups (GU committee of EORTC, UNICANCER, ESMO). He is member of Annals of Oncology editorial board and European Journal of Cancer.

Dr. Stephane De Botton is working as a Head of Institut Gustave roussy, France He holds a Master's Degree followed by a Bachelor’s Degree. He is extending his valuable service as a Research Scholar in Institut Gustave's Rousey France and has been a recipient of many awards and grants. His research experience includes various programs, contributions, and participation in different countries for diverse fields of study. His research interests as a Research Scholar reflect in his wide range of publications in various national and international journals. His greatest interest is in hematological oncology.